The role of difluprednate ophthalmic emulsion in clinical practice

Clinical Ophthalmology

Volumn 3, Issue 1, 2009, Pages 381-390

  Jamal, Karim N ^a,b   Callanan, David G ^a  

^a TEXAS RETINA ASSOCIATES   (United States)

^b RETINAL CONSULTANTS OF ARIZONA   (United States)

Author keywords

Difluprednate; Emulsion; Ophthalmic surgery; Steroid

Indexed keywords

BETAMETHASONE; CORTICOSTEROID; DIFLUPREDNATE;

CLINICAL PRACTICE; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG SAFETY; EMULSION; EYE INFECTION; HUMAN; INTRAOCULAR HYPERTENSION; IRIDOCYCLITIS; OPTIC NERVE LESION; POSTOPERATIVE INFLAMMATION; REVIEW; SUBCAPSULAR CATARACT; VISUAL FIELD DEFECT;

EID: 77953437646     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Apple DJ, Solomon KD, Tetz MR, et al. Posterior capsule opacification. Surv Ophthalmol. 1992;37:73-116.
2. Miyake K, Maekubo K, Miyake Y, et al. Pupillary fibrin membrane; a frequent early complication after posterior chamber lens implantation in Japan. Ophthalmol. 1989;96:1228-1233.
3. Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th Edition. New York: McGraw-Hill; 2001. p. 1649-1677.
4. Sanders DR, Kraff M. Steroidal and nonsteroidal anti-inflammatory agents. Effect on postsurgical inflammation and blood-aqueous humor barrier breakdown. Arch Ophthalmol. 1984;102(10):1453-1456.
5. Korenfeld M. Difluprednate: changing the landscape of ocular pharmacology. Expert Rev Ophthamol. 2008;3(6):619-625.
6. Bikowski J. The position not the presence of the halogen in corticosteroids influences potency and side effects. J Drugs Dermatol. 2006;5(2):125-130.
7. Yamaguchi M, Yasueda S, Isowaki A, et al. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int J Pharmaceutics. 2005;301:121-128.
8. Sweetana S, Akers MJ. Solubility principles and practices for parenteral drug dosage form development. J Pharm Sci Technol. 1996;50: 330-342.
9. Rajagopalan N, Dicken CM, Ravin LJ, et al. A study of the solubility of amphotericin B in nonaqueous solvent systems. J Parenter Sci Technol. 1988;42:97-102.
10. Loftsson T, Petersen DS. Cyclodextrin solubilization of ETH-615, a zwitterionic drug. Drug Dev Ind Pharm. 1998;24:365-370.
11. Alvarez-Nunez FA, Yalkowsky SH. Solubilization of diazepam. J Pharm Sci Technol. 1998;52:33-36.
12. Deicke A, Suverkrup R. Dose uniformity and redispersibility of pharmaceutical suspensions. I: quantification and mechanical modeling of human shaking behaviour. Eur J Pharm Biopharm. 1999;48: 225-232.
13. Diestelhorst M, Kwon KA, Suverkrup R. Dose uniformity of ophthalmic suspensions. J Cataract Refract Surg. 1998;24:672-677.
14. Vandamme T. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002;21: 15-34.
15. Koycha M, Rochat MH, Verain A. Physicochemical stability of emulsions: application to mixtures for parenteral nutrition. J Pharm Belg. 1988;43:413-424.
16. Tamilvanan S, Benita S. The potential of lipid emulsion for ocular drug delivery of lipophilic drugs. Eur J Pharm Biopharm. 2004;58:357-368.
17. Fujino A, Ohtu S, Shibata K, et al. Studies on the metabolic fate of difluprednate (DFBA). 3. Metabolism in rats and rabbits after subcutaneous administration. Pharmacometrics. 1985;29:713-723.
18. Tajika T, Shirasaki Y, Kimura M, et al. Ocular distribution and metabolism after instillation of difluprednate ophthalmic emulsion in rabbits. The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B744, Program 2654. Fort Lauderdale, FL, USA, 6-10 May 2007.
19. Yasueda S, Kimura M, Ohtori A, et al. Analysis of an anti-inflammatory steroidal drug, difluprednate, in aqueous humor by combination of semimicro HPLC and column switching method. J Pharm Biomed Anal. 2003;30:1735-1742.
20. Sakaki H, Mito C, Nemoto S, et al. Preclinical toxicity of difluprednate ophthalmic emulsion. The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B743, Program 2653. Fort Lauderdale, FL, USA, 6-10 May 2007.
21. Inoue J, Yamaguchi M, Sakaki H, et al. Preclinical pharmacokinetics of difluprednate ophthalmic emulsion. The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B741, Program 2651. Fort Lauderdale, FL, USA, 6-10 May 2007.
22. Kida T, Takahaski H, Tsuzuki M, et al. Difluprednate emulsion inhibits postoperative inflammation in rabbit paracentesis model. The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B745, Program 2655. Fort Lauderdale, FL, USA, 6-10 May 2007.
23. Okumura A, Tsuzuki M, Wada T, et al. Efficacy of difluprednate ophthalmic emulsion in preclinical studies of uveitisThe 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B742, Program 2652. Fort Lauderdale, FL, USA, 6-10 May 2007.
24. Senju Pharmaceutical Co., Ltd., Osaka, Japan. Phase I clinical study of difluprednate: single instillation. Mar 1999. Data on file.
25. Senju Pharmaceutical Co., Ltd., Osaka, Japan. Phase I clinical study of difluprednate: repeated instillation. Mar 1999. Data on file.
26. Senju Pharmaceutical Co., Ltd., Osaka, Japan. Phase IIa clinical study of difluprednate 0.002% and 0.05% in the treatment of postoperative inflammation. Feb 2002. Data on file.
27. Senju Pharmaceutical Co., Ltd., Osaka, Japan. Phase IIb clinical study of difluprednate 0.05% vs betamethasone 0.1% in the treatment of postoperative inflammation. Apr 2004. Data on file.
28. Ohji M, Tano Y, Hida T, et al. Efficacy and safety results of a phase III study of difluprednate ophthalmic emulsion 0.05% in postoperative inflammation. The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B807, Program 3903. Fort Lauderdale, FL, USA, 6-10 May 2007.
29. Korenfeld MS, Silverstein SM, Cooke DL, et al. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg. 2009;35:26-34.
30. Ohno S, Mochizuki M, Usui M, et al. A phase III noninferiority study of difluprednate ophthalmic emulsion 0.05% in the treatment of anterior uveitis. The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B808, Program 3904. Fort Lauderdale, FL, USA, 6-10 May 2007.
31. Mochizuki M, Ohno S, Usui M, et al. A phase III open-label clinical study of difluprednate ophthalmic emulsion 0.05% in the treatment of severe refractory anterior uveitis. The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B809, Program 3905. Fort Lauderdale, FL, USA, 6-10 May 2007.
32. Sirion Therapeutics, Inc., Tampa, FL. A phase III multicenter, randomized, double-masked study of the safety and efficacy of difluprednate 0.05% ophthalmic emulsion compared to prednisolone acetate 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. Dec 2008. Data on file.
33. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye. Arch Ophthalmol. 1963;70:482-491.
34. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. II. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol. 1963;70:492-499.
35. Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol. 2005;5:459-463.
36. Price F. Do you welcome BAK? Weighing the toxicity risk. Optometric Management. 2004 Mar [accessed 2009 Apr 5]. Available from: http://www.optometric.com/article.aspx?articleZ71020.
37. Dart J. Corneal toxicity: the epithelium and stroma in iatrogenic and factitious disease. Eye. 2003;17:886-892.
38. Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol. 2007;18: 134-139.
39. Abelson MB, Washburn S. The downside of tear preservatives. Rev Ophthalmol. 2002;9:102-106.
40. Negi AK, Browning AC, Vernon SA. Single perioperative triamcinolone injection versus standard postoperative steroid drops after uneventful phacoemulsification surgery: randomized controlled trial. J Cataract Refract Surg. 2006;32(3):468-474.
41. 11beta-hydroxysteroid- dehydrogenases. Horm Metab Res. 2004;36:423-429.
42. Dunne JA, Jacobs N, Morrison A, et al. Efficacy in anterior uveitis of two known steroids and topical tolmetin. Br J Ophthalmol. 1985; 69:120-125.
43. Statistics on Blindness and Blinding Diseases in the United States [web page]. The University of Washington Department of Ophthalmology; c1997-2004 [updated 2004 Jan 1; accessed 2009 Apr 5]. Available from: http://depts. washington.edu/ophthweb/statistics.html.
44. Frequently Asked Questions [web page]. American Uveitis Society; c2002 [accessed 2009 Apr 5]. Available at: http://www.uveitissociety. org/pages/faq.html.
45. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150:1881-1884.